Upgrade to SI Premium - Free Trial

IDEX Reports First Quarter Results

April 29, 2026 7:00 AM

Highlights

(All comparisons are against the prior year period unless otherwise noted)

NORTHBROOK, Ill.--(BUSINESS WIRE)-- IDEX Corporation (NYSE: IEX) today announced its financial results for the three-month period ended March 31, 2026.

“We delivered a strong first quarter, with results ahead of our expectations led by continued momentum in our growth platforms within our Health & Science Technologies segment,” said Eric D. Ashleman, IDEX Corporation Chief Executive Officer and President.

“Our first quarter results demonstrate that our strategy is working, with strong execution across the portfolio and increasing traction in the markets where we are choosing to compete. The application of 8020 continues to sharpen our priorities and reallocate resources toward opportunities with stronger growth and margin profiles.”

“Based on this momentum, we are raising our full-year guidance and are encouraged by how our strategies are translating into higher-quality growth. We remain focused on disciplined execution as we continue to build long-term value at IDEX.”

Outlook(1)

(1) The Company does not reconcile its forward-looking non-GAAP measures to the most directly comparable U.S. GAAP financial measure because the timing and magnitude of certain items, including future foreign exchange impacts, acquisitions, divestitures, restructuring costs, impairments, tax impacts, and other special items, cannot be reasonably estimated at this time without unreasonable effort. The unavailable information could have a significant impact on GAAP results.

Consolidated Financial Results

Three Months Ended March 31,

(Dollars in millions, except per share amounts)

2026

2025

Increase (Decrease)

U.S. GAAP Results

Orders

$

988.3

$

871.9

$

116.4

Change in reported orders

13%

Net sales

886.9

814.3

72.6

Change in reported net sales

9%

Gross profit

398.1

368.9

29.2

Gross margin

44.9%

45.3%

(40) bps

Net income attributable to IDEX

120.0

95.5

24.5

Net income margin

13.5%

11.7%

180 bps

Diluted EPS attributable to IDEX

1.61

1.26

0.35

Cash flows from operating activities

103.7

105.7

(2.0)

Operating cash flow as a percent of net income

86%

111%

NM

Non-GAAP Results*

Change in organic orders

10%

Change in organic sales

5%

Adjusted gross profit(1)

398.1

368.9

29.2

Adjusted gross margin(1)

44.9%

45.3%

(40) bps

Adjusted net income attributable to IDEX

148.6

133.0

15.6

Adjusted EBITDA

230.4

208.0

22.4

Adjusted EBITDA margin

26.0%

25.5%

50 bps

Adjusted diluted EPS attributable to IDEX

2.00

1.75

0.25

Free cash flow

86.0

91.4

(5.4)

Free cash flow conversion

58 %

69 %

NM

NM – Not Meaningful

*Each of these items below are non-GAAP measures. See the definitions of these non-GAAP measures in the section in this release titled “Non-GAAP Measures of Financial Performance” and reconciliations to their most directly comparable GAAP financial measures in the reconciliation tables at the end of this release.

(1) Adjusted gross profit is calculated as Gross profit plus fair value inventory step-up charges. Adjusted gross margin is calculated as Adjusted gross profit divided by Net sales. There were no fair value inventory step-up charges recorded during the three months ended March 31, 2026 or March 31, 2025.

Segment Financial Results

Three Months Ended March 31,(1)

(Dollars in millions)

2026

2025

Increase (Decrease)

Health & Science Technologies

Net sales

$

398.4

$

341.5

$

56.9

Change in reported net sales

17%

Change in organic sales*

11%

Adjusted EBITDA(2)

106.0

87.4

18.6

Adjusted EBITDA margin

26.6%

25.6%

100 bps

Fluid & Metering Technologies

Net sales

$

301.5

$

290.5

$

11.0

Change in reported net sales

4%

Change in organic sales*

2%

Adjusted EBITDA(2)

98.7

95.3

3.4

Adjusted EBITDA margin

32.7%

32.8%

(10) bps

Fire & Safety/Diversified Products

Net sales

$

188.3

$

184.3

$

4.0

Change in reported net sales

2%

Change in organic sales*

(1%)

Adjusted EBITDA(2)

55.8

54.2

1.6

Adjusted EBITDA margin

29.7%

29.4%

30 bps

*These are non-GAAP measures. See the definitions of these non-GAAP measures in the section in this release titled “Non-GAAP Measures of Financial Performance” and reconciliations to their most directly comparable GAAP financial measures in the reconciliation tables at the end of this release.

(1) Three month data includes the results of the acquisition of Micro-LAM, Inc. (“Micro-LAM”) (July 2025) in the HST segment.

(2) Segment Adjusted EBITDA excludes unallocated corporate costs which are included in Corporate and other.

Health & Science Technologies Segment

Fluid & Metering Technologies Segment

Fire & Safety/Diversified Products Segment

Corporate Costs

Corporate costs included in consolidated Adjusted EBITDA were $30.1 million during the first quarter 2026, up slightly from $28.9 million during the same prior year period driven by higher employee-related costs.

Conference Call

IDEX will host its first quarter earnings conference call on Wednesday, April 29, 2026 at 8:00 a.m. CT. The call will be an audio webcast and accessible on the Company's Investor Relations site at https://investors.idexcorp.com. Associated earnings presentation materials will be available on the Company's website prior to the call.

Interested parties can access the conference by dialing 888.596.4144 and using confirmation code #2518354. Please connect five minutes prior to the start of the conference call.

A replay of the earnings call and associated earnings presentation materials will be available on the Company’s website after the call.

Forward-Looking Statements

This news release contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may relate to, among other things, the Company’s second quarter 2026 and full year 2026 outlook including expected organic sales and expected adjusted earnings per share and the assumptions underlying these expectations, capital return strategy, anticipated future acquisition behavior and the anticipated benefits and performance of the Company’s recent or future acquisitions, resource and capital deployment and focus and organic and inorganic growth, the Company’s ability to adapt to macroeconomic challenges, anticipated impacts of tariffs and global trade policies and changes in law, anticipated trends in end markets, including expectations regarding future order volumes and order patterns, anticipated growth initiatives and expansions and execution of those growth initiatives and are indicated by words or phrases such as “anticipates,” “estimates,” “plans,” “guidance,” “expects,” “projects,” “forecasts,” “should,” “could,” “will,” “likely to be,” “management believes,” “the Company believes,” “the Company intends” and similar words or phrases. These statements are subject to inherent uncertainties and risks that could cause actual results to differ materially from those anticipated at the date of this news release.

The risks and uncertainties include, but are not limited to, the following: levels of industrial activity and economic conditions in the U.S. and other countries around the world, including uncertainties in the financial markets; pricing pressures, including inflation and rising interest rates, and other competitive factors and levels of capital spending in certain industries; the impact of severe weather events, natural disasters and public health threats; economic and political consequences resulting from terrorist attacks, wars and global conflicts; the Company’s ability to make acquisitions and to integrate and operate acquired businesses on a profitable basis; cybersecurity incidents; the continued growth of artificial intelligence (“AI”) and any related changes to demand in AI-driven markets served by the Company’s customers; the relationship of the U.S. dollar to other currencies and its impact on pricing and cost competitiveness; political and economic conditions in countries in which the Company operates; developments with respect to trade policy and existing, new or increased tariffs or other similar measures; changes to applicable laws and regulations, including tax laws; interest rates; capacity utilization and the effect this has on costs; labor markets; supply chain conditions; market conditions and material costs; risks related to environmental, social and corporate governance issues, including those related to climate change and sustainability; and developments with respect to contingencies, such as litigation and environmental matters.

Additional factors that could cause actual results to differ materially from those reflected in the forward-looking statements include, but are not limited to, the risks discussed in the “Risk Factors” section included in the Company’s most recent annual report on Form 10-K and the Company’s subsequent quarterly reports filed with the United States Securities and Exchange Commission (“SEC”) and the other risks discussed in the Company’s filings with the SEC. The forward-looking statements included here are only made as of the date of this news release, and management undertakes no obligation to publicly update them to reflect subsequent events or circumstances, except as may be required by law. Investors are cautioned not to rely unduly on forward-looking statements when evaluating the information presented here.

About IDEX

IDEX Corporation (NYSE: IEX), a global engineered products company, is comprised of three primary business segments – Health & Science Technologies, Fluid & Metering Technologies, and Fire & Safety/Diversified Products. Thousands of IDEX employees around the world design and manufacture highly engineered components and applied solutions that are vital to the advances of modern life and help IDEX live its purpose – Trusted Solutions, Improving Lives™. From satellite communications to water systems, from medical diagnostic components to emergency rescue tools and more, we collaborate with customers in the most critical industries to develop solutions that make the world better today and into the future. Founded in 1988, IDEX now includes more than 50 dynamic businesses around the world and manufacturing operations in more than 20 countries.

For further information on IDEX Corporation and its business units, visit the Company’s website at www.idexcorp.com.

(Financial reports follow)

IDEX CORPORATION

Condensed Consolidated Statements of Income

(in millions, except per share amounts)

(unaudited)

Three Months Ended March 31,

2026

2025

Net sales

$

886.9

$

814.3

Cost of sales

488.8

445.4

Gross profit

398.1

368.9

Selling, general and administrative expenses

218.3

209.4

Restructuring expenses and asset impairments

7.4

17.5

Operating income

172.4

142.0

Other (income) expense – net

(0.6

)

1.4

Interest expense – net

16.0

16.1

Income before income taxes

157.0

124.5

Provision for income taxes

37.1

29.1

Net income

119.9

95.4

Net loss attributable to noncontrolling interest

0.1

0.1

Net income attributable to IDEX

$

120.0

$

95.5

Earnings per Common Share:

Basic earnings per common share attributable to IDEX

$

1.61

$

1.26

Diluted earnings per common share attributable to IDEX

$

1.61

$

1.26

Share Data:

Basic weighted average common shares outstanding

74.3

75.7

Diluted weighted average common shares outstanding

74.4

75.8

IDEX CORPORATION

Condensed Consolidated Balance Sheets

(in millions)

(unaudited)

March 31, 2026

December 31, 2025

Assets

Current assets

Cash and cash equivalents

$

586.2

$

580.0

Receivables – net

553.0

521.7

Inventories – net

501.0

479.4

Other current assets

76.5

62.1

Total current assets

1,716.7

1,643.2

Property, plant and equipment – net

462.3

468.0

Goodwill

3,390.2

3,414.5

Intangible assets - net

1,200.2

1,247.4

Other noncurrent assets

149.2

153.9

Total assets

$

6,918.6

$

6,927.0

Liabilities and equity

Current liabilities

Trade accounts payable

$

224.8

$

224.7

Accrued expenses

280.6

297.0

Current portion of long-term borrowings

0.5

0.7

Dividends payable

0.1

53.0

Total current liabilities

506.0

575.4

Long-term borrowings – net

1,871.8

1,820.1

Deferred income taxes

299.5

303.0

Other noncurrent liabilities

192.9

202.3

Total liabilities

2,870.2

2,900.8

Shareholders' equity

Preferred stock

Common stock

0.9

0.9

Treasury stock

(1,453.6

)

(1,423.2

)

Additional paid-in capital

868.5

892.1

Retained earnings

4,620.1

4,500.1

Accumulated other comprehensive income

13.9

57.6

Total shareholders' equity

4,049.8

4,027.5

Noncontrolling interest

(1.4

)

(1.3

)

Total equity

4,048.4

4,026.2

Total liabilities and equity

$

6,918.6

$

6,927.0

IDEX CORPORATION

Condensed Consolidated Statements of Cash Flows

(in millions)

(unaudited)

Three Months Ended March 31,

2026

2025

Cash flows from operating activities

Net income

$

119.9

$

95.4

Adjustments to reconcile net income to net cash flows provided by operating activities:

Asset impairments

4.8

Depreciation

19.9

18.4

Amortization of intangible assets

33.8

31.5

Share-based compensation expense

15.8

13.6

Deferred income taxes

(0.6

)

0.9

Changes in (net of the effect from acquisitions/divestitures and foreign currency translation):

Receivables – net

(35.4

)

(12.3

)

Inventories – net

(25.5

)

(34.9

)

Other current assets

(15.1

)

(7.0

)

Trade accounts payable

0.6

9.6

Deferred revenue

4.2

8.8

Accrued expenses

(18.8

)

(17.9

)

Other – net

0.1

(0.4

)

Net cash flows provided by operating activities

103.7

105.7

Cash flows from investing activities

Capital expenditures

(17.7

)

(14.3

)

Acquisition of business, net of cash acquired

4.2

Other – net

(2.7

)

0.1

Net cash flows used in investing activities

(20.4

)

(10.0

)

Cash flows from financing activities

Borrowings under revolving credit facilities

100.0

Payments under revolving credit facilities

(45.3

)

(30.2

)

Cash dividends paid to shareholders

(52.8

)

(52.4

)

Proceeds (payments) from share issuances, net of shares withheld for taxes

5.8

(0.5

)

Repurchases of common stock

(76.3

)

(50.0

)

Other – net

(0.2

)

(0.2

)

Net cash flows used in financing activities

(68.8

)

(133.3

)

Effect of exchange rate changes on cash and cash equivalents

(8.6

)

10.9

Net increase (decrease) in cash and cash equivalents and restricted cash

5.9

(26.7

)

Cash and cash equivalents and restricted cash at beginning of year(1)

585.9

638.9

Cash and cash equivalents and restricted cash at end of period(1)

$

591.8

$

612.2

(1)

The Company has restricted cash related to certain letters of credit and is required to keep these balances in separate accounts for the duration of the letter of credit agreements. The underlying letters of credit expire between June 2026 and July 2027. The Company also has restricted cash related to funds held in escrow for the payment of certain merger consideration in connection with the acquisition of Micro-LAM. These payments are expected to be paid between July 2026 and January 2028. Restricted cash is included in the Condensed Consolidated Balance Sheets as follows:

Restricted Cash

March 31, 2026

December 31, 2025

March 31, 2025

December 31, 2024

Other current assets

$

2.7

$

3.0

$

16.5

$

18.1

Other noncurrent assets

2.9

2.9

1.6

Total

$

5.6

$

5.9

$

18.1

$

18.1

IDEX CORPORATION

Company and Segment Financial Information

(in millions)

(unaudited)

Three Months Ended March 31,

2026

2025

Net sales

Health & Science Technologies

$

398.4

$

341.5

Fluid & Metering Technologies

301.5

290.5

Fire & Safety/Diversified Products

188.3

184.3

Eliminations

(1.3

)

(2.0

)

Total IDEX

$

886.9

$

814.3

Depreciation

Health & Science Technologies

$

12.5

$

11.7

Fluid & Metering Technologies

4.9

4.4

Fire & Safety/Diversified Products

2.4

2.2

Corporate Office

0.1

0.1

Total IDEX

$

19.9

$

18.4

Amortization of intangible assets

Health & Science Technologies

$

27.1

$

24.6

Fluid & Metering Technologies

5.4

5.3

Fire & Safety/Diversified Products

1.3

1.6

Total IDEX

$

33.8

$

31.5

Restructuring expenses and asset impairments

Health & Science Technologies

$

1.1

$

11.4

Fluid & Metering Technologies

5.1

4.2

Fire & Safety/Diversified Products

0.3

1.6

Corporate Office

0.9

0.3

Total IDEX

$

7.4

$

17.5

Non-GAAP Measures of Financial Performance

The Company prepares its public financial statements in conformity with accounting principles generally accepted in the United States of America (U.S. GAAP). The Company supplements certain U.S. GAAP financial performance metrics with non-GAAP financial performance metrics. Management believes these non-GAAP financial performance metrics provide investors with greater insight, transparency and a more comprehensive understanding of the financial information used by management in its financial and operational decision making because certain of these adjusted metrics exclude items not reflective of ongoing operations, as identified in the reconciliations below. Reconciliations of non-GAAP financial performance metrics to their most directly comparable U.S. GAAP financial performance metrics are defined and presented below and should not be considered a substitute for, nor superior to, the financial data prepared in accordance with U.S. GAAP. Due to rounding, numbers presented throughout this and other documents may not add up or recalculate precisely.

All table footnotes can be found at the end of this Non-GAAP Measures section. There were no adjustments to U.S. GAAP financial performance metrics other than the items noted below.

Table 1: Reconciliations of the Change in Net Sales to Organic Sales

HST

FMT

FSDP

IDEX

Three Months Ended March 31, 2026

Change in net sales

17

%

4

%

2

%

9

%

Less:

Net impact from acquisitions/divestitures(1)

3

%

%

%

1

%

Impact from foreign currency(2)

3

%

2

%

3

%

3

%

Change in organic sales

11

%

2

%

(1

%)

5

%

Table 2: Reconciliations of Reported-to-Adjusted Net Income Attributable to IDEX and Diluted EPS Attributable to IDEX (in millions, except per share amounts)

Three Months Ended March 31,

2026

2025

Reported net income attributable to IDEX

$

120.0

$

95.5

Restructuring expenses and asset impairments

7.4

17.5

Tax impact on restructuring expenses and asset impairments

(1.7

)

(4.1

)

Gain on legal settlement(3)

(3.7

)

Tax impact on gain of legal settlement

0.8

Acquisition-related intangible asset amortization

33.8

31.5

Tax impact on acquisition-related intangible asset amortization

(8.0

)

(7.4

)

Adjusted net income attributable to IDEX

$

148.6

$

133.0

Reported diluted EPS attributable to IDEX

$

1.61

$

1.26

Restructuring expenses and asset impairments

0.10

0.23

Tax impact on restructuring expenses and asset impairments

(0.02

)

(0.05

)

Gain on legal settlement(3)

(0.05

)

Tax impact on gain of legal settlement

0.01

Acquisition-related intangible asset amortization

0.46

0.41

Tax impact on acquisition-related intangible asset amortization

(0.11

)

(0.10

)

Adjusted diluted EPS attributable to IDEX

$

2.00

$

1.75

Diluted weighted average shares outstanding

74.4

75.8

Table 3: Reconciliations of Net Income to Adjusted EBITDA (dollars in millions)

Three Months Ended March 31,

2026

2025

Reported net income

$

119.9

$

95.4

Provision for income taxes

37.1

29.1

Interest expense - net

16.0

16.1

Depreciation

19.9

18.4

Amortization

33.8

31.5

Restructuring expenses and asset impairments

7.4

17.5

Gain on legal settlement(3)

(3.7

)

Adjusted EBITDA

$

230.4

$

208.0

Adjusted EBITDA Components

HST

$

106.0

$

87.4

FMT

98.7

95.3

FSDP

55.8

54.2

Corporate and other

(30.1

)

(28.9

)

Total Adjusted EBITDA

$

230.4

$

208.0

Net sales

$

886.9

$

814.3

Net income margin

13.5

%

11.7

%

Adjusted EBITDA margin

26.0

%

25.5

%

Table 4: Reconciliations of Cash Flows from Operating Activities to Free Cash Flow (dollars in millions)

Three Months Ended March 31,

2026

2025

Cash flows from operating activities

$

103.7

$

105.7

Less: Capital expenditures

17.7

14.3

Free cash flow

$

86.0

$

91.4

Reported net income attributable to IDEX

$

120.0

$

95.5

Adjusted net income attributable to IDEX

148.6

133.0

Operating cash flow as a percent of net income

86

%

111

%

Free cash flow conversion

58

%

69

%

(1) Represents the sales from acquired or divested businesses during the first 12 months of ownership or prior to divestiture.

(2) The portion of sales attributable to foreign currency translation is calculated as the difference between (a) the period-to-period change in organic sales, and (b) the period-to-period change in organic sales after applying prior period foreign exchange rates to the current year period.

(3) Gain on legal settlement represents settlement funds received in excess of legal costs incurred related to a patent infringement lawsuit within the FMT segment.

Investor Contact:

Jim Giannakouros, CFA

Vice President, Investor Relations

(847) 313-9506

Source: IDEX Corporation

Categories

Business Wire Press Releases